Testing MS-553 for relapsed or hard-to-treat CLL or SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new pill called MS-553 for patients with CLL or SLL that has come back or not responded to other treatments. It aims to see if this drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with CLL or SLL that needs treatment or needs to be shrunk before a stem cell transplant.
- Your CLL or SLL has come back or did not respond to prior therapy.
- You do not have a current change of your CLL/SLL into a more aggressive lymphoma (like non-Hodgkin or Hodgkin lymphoma).
- You do not have an active autoimmune condition where your immune system attacks your blood cells, like low red blood cells or platelets that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Hear when a new CLL (Chronic Lymphocytic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.